<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>132-CLINDAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLINDAMYCIN" rxcui="2582">
<ATC code="D10AF01" />
<ATC code="G01AA10" />
<ATC code="J01FF01" />
<ATC code="D10AF51" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the clindamycin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>132-CLINDAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLINDAMYCIN" rxcui="2582">
<ATC code="D10AF01" />
<ATC code="G01AA10" />
<ATC code="J01FF01" />
<ATC code="D10AF51" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforced testing of the blood dosages of ciclosporin and possible increase of its dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>132-CLINDAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLINDAMYCIN" rxcui="2582">
<ATC code="D10AF01" />
<ATC code="G01AA10" />
<ATC code="J01FF01" />
<ATC code="D10AF51" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage.</COMMENT>
</INTERACTION>
</INTERACTIONS>
